Pasireotide LAR in patients with metastatic carcinoid tumors: Interim safety results from a randomized, multicenter phase I study

被引：0
|
作者：
Wolin, E. [1 ]
Kvols, L. [2 ]
Ezzat, S. [3 ]
Kocha, W. [4 ]
Van Cutsern, E. [5 ]
Schonherr, U. [6 ]
Fandi, A. [7 ]
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[2] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[3] Univ Toronto, Ontario Canc Inst, Toronto, ON M5S 1A1, Canada
[4] London Reg Canc Ctr, London, ON N6A 4L6, Canada
[5] Univ Hosp Gasthuisberg, Digest Oncol Unit, B-3000 Leuven, Belgium
[6] Novartis Pharma AG, Basel, Switzerland
[7] Novartis Pharmaceut Corp, E Hanover, NJ USA
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：54 / 54
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetics, Pharmacodynamics, and Safety of Pasireotide LAR in Patients With Acromegaly: A Randomized, Multicenter, Open-Label, Phase I Study
    Petersenn, Stephan
    Bollerslev, Jens
    Arafat, Ayman M.
    Schopohl, Jochen
    Serri, Omar
    Katznelson, Laurence
    Lasher, Janet
    Hughes, Gareth
    Hu, Ke
    Shen, George
    Resendiz, Karina Hermosillo
    Giannone, Vanessa
    Beckers, Albert
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (11): : 1308 - 1317
  • [2] Safety and efficacy of pasireotide (S0M230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: Results of a phase II study.
    Kvols, L.
    Wiedenmann, B.
    Oberg, K.
    Glusman, J. E.
    O'dorisio, T. M.
    De Herder, W.
    Gao, B.
    Arnold, R.
    Anthony, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 198S - 198S
  • [3] Phase II Clinical Trial of Pasireotide LAR in Patients with Metastatic Neuroendocrine Tumors
    Cives, M.
    Kunz, P.
    Nguyen, P.
    Jump, H.
    Vilay, K.
    Valone, T.
    Strosberg, J. R.
    NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 270 - 270
  • [4] Phase II clinical trial of pasireotide LAR in patients with metastatic neuroendocrine tumors
    Strosberg, Jonathan R.
    Jump, Helen
    Valone, Tiffany
    Weber, Jill
    Khandelwal, Vilay H.
    Kunz, Pamela L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [5] A Multicenter, Randomized, Blinded, Phase 3 Study of Pasireotide LAR vs Octreotide LAR in Patients with Metastatic Neuroendocrine Tumors (NET) with Disease-Related Symptoms Inadequately Controlled by Somatostatin Analogs
    Wolin, Edward M.
    Jarzab, Barbara
    Eriksson, Barbro
    Walter, Thomas
    Toumpanakis, Christos
    Morse, Michael
    Tomassetti, Paola
    Weber, Matthias
    Fogelman, David
    Ramage, John
    Poon, Donald
    Huang, Jerry
    Hudson, Michelle
    Li, Jiang
    Pasieka, Janice L.
    Mahamat, Abakar
    Swahn, Fredrik
    Newell-Price, John
    Mansoor, Was
    Oberg, Kjell
    PANCREAS, 2014, 43 (03) : 508 - 508
  • [6] Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study
    Edward M. Wolin
    Ke Hu
    Gareth Hughes
    Emmanuel Bouillaud
    Vanessa Giannone
    Karina Hermosillo Resendiz
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 387 - 395
  • [7] Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study
    Wolin, Edward M.
    Hu, Ke
    Hughes, Gareth
    Bouillaud, Emmanuel
    Giannone, Vanessa
    Resendiz, Karina Hermosillo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (02) : 387 - 395
  • [8] A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs
    Wolin, Edward M.
    Jarzab, Barbara
    Eriksson, Barbro
    Walter, Thomas
    Toumpanakis, Christos
    Morse, Michael
    Tomassetti, Paola
    Weber, Matthias
    Fogelman, David R.
    Ramage, John
    Poon, Donald
    Huang, Jerry M.
    Hudson, Michelle
    Zhi, Xin
    Pasieka, Janice L.
    Mahamat, Abakar
    Swahn, Fredrik
    Newell-Price, John
    Mansoor, Wasat
    Oberg, Kjell E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] Phase I dose-escalation study of pasireotide LAR in patients with advanced neuroendocrine tumors.
    Phan, Alexandria T.
    Wolin, Edward M.
    Chan, Jennifer A.
    Huang, Jerry M.
    Hudson, Michelle
    Hughes, Gareth
    Shen, Guoxiang
    Strosberg, Jonathan R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Efficacy, Safety and Pharmacokinetic Results from a Phase II Study of Pasireotide (SOM230) in the Treatment of Patients with Metastatic NETs Refractory or Resistant to Octreotide LAR
    Kvols, L.
    Wiedenmann, B.
    Oberg, K.
    Mohideen, P.
    O'Dorisio, T.
    de Herder, W.
    Hughes, G.
    Arnold, R.
    Anthony, L.
    NEUROENDOCRINOLOGY, 2010, 92 (01) : 42 - 43
12345